Strides Pharma to sell majority stake in Pivot Path to Ascent Capital-led consortium

Mumbai: Strides Pharma Science has announced a major strategic deal involving its wholly-owned subsidiary, Pivot Path Private Limited. The company has partnered with Ascent Capital to unlock value and support the next growth phase of the business.Strategic PartnershipThe board of Strides approved an investment by a consortium led by Ascent Capital along with co-investor Vintage Classic.As part of the transaction, Strides will sell a majority stake in Pivot Path for around Rs 100 crore. At the same time, Ascent Capital will invest Rs 50 crore as fresh capital into the subsidiary. Anupam Rasayan To Acquire Up To 43.3% Stake In Bliss GVS Pharma, Deal Valued At Around ₹1,370 CroreThis funding will help Pivot Path expand faster and strengthen its market position.Deal StructureStrides will receive the sale consideration in two parts.Around Rs 75 crore will be paid at the time of closing, while the remaining Rs 25 crore will be paid after one year.After the transaction, Strides’ ownership in Pivot Path will reduce sharply.The new shareholding structure will include 19.95 percent stake for Strides, 65.05% for investors, and 15 percent reserved for ESOPs.Following this, Pivot Path will be reclassified as an associate company instead of a wholly-owned subsidiary. Strides Pharma Q4 Profit Rises 51% To ₹129 Crore, Revenue Climbs To ₹1,323 Crore On Strong Ex-US GrowthBusiness ExpansionPivot Path originated within Arco Lab, Strides’ Global Capability Centre. Over time, it developed expertise in life sciences consulting, digital transformation, compliance, and technology-driven services.As demand from pharmaceutical and life sciences companies increased, the business evolved into an independent platform serving large industry clients.The company was formally carved out into a separate entity in May 2026.Growth FocusStrides said the partnership reflects Pivot Path’s strong business potential and growing demand for specialised services.The company believes external investment will accelerate growth, improve capabilities, and create long-term value.The transaction is expected to be completed by June 30, while the capital infusion is likely to be completed by July 31.

Strides will hold a 19.95 per cent stake in Pivot Path, while investors will hold 65.05 per cent with ESOP Pool at 15 per cent

Following the completion of the transaction, Pivot Path will be reclassified from a wholly owned subsidiary to an associate company of Strides

Strides Pharma Science Ltd on Saturday announced divestment of majority stake in its wholly-owned arm Pivot Path for Rs 100 crore to a consortium of investors led by Ascent Capital, along with co-investor Vintage. The board of directors of the company, at its meeting held on June 27, 2026, has approved a strategic investment by a consortium led by Ascent Capital, along with co-investor Vintage Classic, in its wholly owned subsidiary, Pivot Path Pvt Ltd (Pivot Path), Strides Pharma Science Ltd , said in a regulatory filing. The proposed transaction comprises the sale of the majority stake by Strides to Ascent Capital and Vintage Classic for an aggregate consideration of Rs 100 crore and the primary infusion of Rs 50 crore into Pivot Path by Ascent Capital to accelerate the next phase of growth, it added. Strides will receive Rs 75 crore at initial closing and Rs 25 crore on the first anniversary of closing, it added. After the transaction, Strides will hold a 19.95 per cent stake in